Dr. Amy C. Schefler, MD

Dr. Schefler practices at Retina Consultants of Houston in Bellaire, Texas.

Dr. Schefler's NPI, 1609079367, was assigned on June 8, 2007. Dr. Schefler graduated from Weill Cornell Medicine in 2003. Dr. Schefler holds Texas license P2782.

Dr. Schefler's primary practice is Retina Consultants of Houston, at 6300 W S Loop, Bellaire, TX 77401 in Harris County. The practice phone is (713) 524-3434.

Dr. Schefler's primary practice is Retina Consultants of Houston in Bellaire, Texas. Dr. Schefler is also affiliated with Houston Methodist Hospital. Dmand AI also links Dr. Schefler to 1 more hospital, 2 group practices and clinics and 2 medical groups, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Schefler practices, 4 sites in all. Vendor and product names are available with a free account.

Ophthalmology is Dr. Schefler's primary specialty in the NPI Registry, under taxonomy code 207W00000X. Dr. Schefler is board certified in ophthalmology by the American Board of Ophthalmology. Dmand AI has Dr. Schefler's licenses on file in 2 states: Texas and Florida.

Dmand AI lists age-related macular degeneration, dry eye, eyelid inflammation, glaucoma, hypertensive retinopathy, inflammation of iris, laser destruction of retinal or choroid lesions and retinal detachment among the conditions Dr. Schefler treats.

CMS data shows 7,654 Medicare services from Dr. Schefler across 21 procedure codes in 2024, for 610 Medicare patients. Medicare paid $1,219,104 for them.

CMS counts 610 Medicare patients who saw Dr. Schefler in 2024. The largest group is 65 to 74, with 292 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 4% are also on Medicaid. Their average risk score is 1.41, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Schefler's median patient age at 67, with 56% women.

In 2024, Dr. Schefler wrote 394 Medicare Part D claims for 110 patients. 77% of them were for generic drugs. CMS names the drug for 353 of them, across 8 drugs with 11 or more claims each, at $8,046 in total drug cost. In 2023, CMS named 146 claims across 5 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 100 out of 100 for Dr. Schefler for performance year 2024, reported as part of a group. Dr. Schefler accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 101 papers to Dr. Schefler, published from 2006 to 2025. 2021 was the busiest year, with 8. The most frequent topics are Melanoma, Uveal Neoplasms and Retinal Neoplasms. Dr. Schefler has published most often in Retina. Dr. Schefler's most frequent co-authors are Timothy G. Murray, MBA, MD, Prithvi Mruthyunjaya, MD and Sander R. Dubovy, MD.

Dmand AI links Dr. Schefler to 8 clinical trials, 3 of them phase 2 studies. Conditions studied include Uveal Melanoma, Macular Edema and Macular Degeneration. Amy C Schefler, MD sponsors the most, 2.

CMS Open Payments shows 92 general payments to Dr. Schefler from 16 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 53% of the total. Allergan Inc. paid the most, $8,825.

Dmand AI lists 1 award for Dr. Schefler.

Dr. Schefler graduated from Weill Cornell Medicine in 2003. Dr. Schefler is a member of ACS.

Dr. Schefler is in network with 23 carriers, including Aetna, Elevance and United Healthcare. PPO plans come from the most carriers, 14. Check the plan with the practice before a visit.